Literature DB >> 19752029

Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.

Denise Morais da Fonseca1, Celio Lopes Silva, Pryscilla Fanini Wowk, Marina Oliveira E Paula, Simone Gusmão Ramos, Cynthia Horn, Gilles Marchal, Vânia Luiza Deperon Bonato.   

Abstract

Culture filtrate proteins (CFP) are potential targets for tuberculosis vaccine development. We previously showed that despite the high level of gamma interferon (IFN-gamma) production elicited by homologous immunization with CFP plus CpG oligodeoxynucleotides (CFP/CpG), we did not observe protection when these mice were challenged with Mycobacterium tuberculosis. In order to use the IFN-gamma-inducing ability of CFP antigens, in this study we evaluated a prime-boost heterologous immunization based on CFP/CpG to boost Mycobacterium bovis BCG vaccination in order to find an immunization schedule that could induce protection. Heterologous BCG-CFP/CpG immunization provided significant protection against experimental tuberculosis, and this protection was sustained during the late phase of infection and was even better than that conferred by a single BCG immunization. The protection was associated with high levels of antigen-specific IFN-gamma and interleukin-17 (IL-17) and low IL-4 production. The deleterious role of IL-4 was confirmed when IL-4 knockout mice vaccinated with CFP/CpG showed consistent protection similar to that elicited by BCG-CFP/CpG heterologous immunization. These findings show that a single dose of CFP/CpG can represent a new strategy to boost the protection conferred by BCG vaccination. Moreover, different immunological parameters, such as IFN-gamma and IL-17 and tightly regulated IL-4 secretion, seem to contribute to the efficacy of this tuberculosis vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752029      PMCID: PMC2786481          DOI: 10.1128/IAI.00580-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Authors:  Sarah C Gilbert; Jörg Schneider; Carolyn M Hannan; Jiang Ting Hu; Magdalena Plebanski; Robert Sinden; Adrian V S Hill
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

Review 4.  Immune responses to tuberculosis in developing countries: implications for new vaccines.

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2005-08       Impact factor: 53.106

5.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

Authors:  B Bourdin Trunz; Pem Fine; C Dye
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

6.  Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis.

Authors:  A D Roberts; M G Sonnenberg; D J Ordway; S K Furney; P J Brennan; J T Belisle; I M Orme
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

Review 7.  IL-23 and IL-17 in tuberculosis.

Authors:  Shabaana A Khader; Andrea M Cooper
Journal:  Cytokine       Date:  2008-01-22       Impact factor: 3.861

8.  Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.

Authors:  Edgar Badell; Fabienne Nicolle; Simon Clark; Laleh Majlessi; Frédéric Boudou; Angelo Martino; Luiz Castello-Branco; Claude Leclerc; David J M Lewis; Philip D Marsh; Brigitte Gicquel; Nathalie Winter
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

9.  Th1-Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages.

Authors:  James Harris; Sharon S Master; Sergio A De Haro; Monica Delgado; Esteban A Roberts; Jayne C Hope; Joseph Keane; Vojo Deretic
Journal:  Vet Immunol Immunopathol       Date:  2008-10-17       Impact factor: 2.046

10.  Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.

Authors:  Eduardo D C Gonçalves; Vânia Luiza D Bonato; Denise M da Fonseca; Edson G Soares; Izaíra T Brandão; Ana Paula M Soares; Célio L Silva
Journal:  Genet Vaccines Ther       Date:  2007-08-22
View more
  11 in total

Review 1.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

2.  Immunization with Mycobacterium tuberculosis-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in Mice.

Authors:  Claus Aagaard; Niels Peter Hell Knudsen; Iben Sohn; Angelo A Izzo; Hongmin Kim; Emma Holsey Kristiansen; Thomas Lindenstrøm; Else Marie Agger; Michael Rasmussen; Sung Jae Shin; Ida Rosenkrands; Peter Andersen; Rasmus Mortensen
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

3.  Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+) /CD4(+)  Foxp3(+) cells.

Authors:  Paola Fernanda Fedatto; Cássia Alves Sérgio; Marina Oliveira e Paula; Ana Flávia Gembre; Luís Henrique Franco; Pryscilla Fanini Wowk; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Walter Miguel Turato; Célio Lopes Silva; Denise Morais da Fonseca; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

4.  CD11c(+)  CD103(+) cells of Mycobacterium tuberculosis-infected C57BL/6 but not of BALB/c mice induce a high frequency of interferon-γ- or interleukin-17-producing CD4(+) cells.

Authors:  Cássia A Sérgio; Thais B Bertolini; Ana Flávia Gembre; Rafael Q Prado; Vânia L D Bonato
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

5.  Identification of compounds that decrease numbers of Mycobacteria in human macrophages in the presence of serum amyloid P.

Authors:  Wang Xiang; Nehemiah Cox; Richard H Gomer
Journal:  J Leukoc Biol       Date:  2017-08-02       Impact factor: 4.962

6.  Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis.

Authors:  Rajesh Mani; Manish Gupta; Anshu Malik; Ravi Tandon; Rajendra Prasad; Rakesh Bhatnagar; Nirupama Banerjee
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

7.  Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.

Authors:  Markos Abebe; Louise Kim; Graham Rook; Abraham Aseffa; Liya Wassie; Martha Zewdie; Alimuddin Zumla; Howard Engers; Peter Andersen; T Mark Doherty
Journal:  Clin Dev Immunol       Date:  2011-01-04

8.  BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model.

Authors:  Amit Singhal; Vanessa Mathys; Mehdi Kiass; Colette Creusy; Baptiste Delaire; El Moukhtar Aliouat; Véronique Dartois; Gilla Kaplan; Pablo Bifani
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

9.  Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG.

Authors:  Keiichi Taniguchi; Takemasa Takii; Saburo Yamamoto; Jun-Ichi Maeyama; Sumiko Iho; Mitsuo Maruyama; Narushi Iizuka; Yuriko Ozeki; Sohkichi Matsumoto; Tomohiro Hasegawa; Yuuji Miyatake; Saotomo Itoh; Kikuo Onozaki
Journal:  Immun Ageing       Date:  2013-06-22       Impact factor: 6.400

10.  Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis.

Authors:  Debapriya Bhattacharya; Ved Prakash Dwivedi; Santosh Kumar; Madhava C Reddy; Luc Van Kaer; Prashini Moodley; Gobardhan Das
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.